Table 3.
Demographics and baseline characteristics of the total blinded treated patient population
| Variable | Total Patients (n = 676) |
|---|---|
| Male, n (%) | 458 (67.8) |
| White race, n (%) | 593 (87.7) |
| Age | |
| Mean, y (SD) | 60.8 (8.75) |
| Range, y | 45–87 |
| Mean BMI, kg/m2 (SD) | 32.7 (5.81) |
| Nicotine use, n (%)a | |
| User | 153 (22.7) |
| Ex-user | 272 (40.3) |
| Non-user | 250 (37.0) |
| Mean lipid parameters, mg/dL (SD) | |
| Total-C | 157.9 (26.2) |
| LDL-C (direct) | 84.3 (20.9) |
| HDL-C | 39.8 (7.6) |
| TG | 227.5 (118.8) |
| Non-HDL-C | 118.0 (24.9) |
| VLDL-C | 41.7 (20.4) |
| Apo B | 81.0 (15.6) |
| Apo AI | 130.7 (17.9) |
| Apo AII | 34.8 (5.7) |
| Apo CIII-lipoprotein Bb | 1.6 (0.8) |
| hs-CRP, mg/L (SD) | 4.1 (7.8) |
| Mean HDL particles, μmol/L (SD) | |
| Total | 32.3 (4.9) |
| Small | 25.1 (5.3) |
| Medium | 3.3 (3.8) |
| Large | 3.9 (1.9) |
| Mean LDL particles, nmol/L (SD) | |
| Total | 1,118 (277) |
| Small | 919 (275) |
| Large | 153 (112) |
| IDL | 46 (38) |
| Mean VLDL particles, nmol/L (SD) | |
| Total | 93 (35) |
| Small | 38 (17) |
| Medium | 48 (23) |
| Large | 8 (7) |
| VLDL TG, mg/dL (SD) | 155.4 (83.2) |
Apo apolipoprotein; BMI body mass index; C cholesterol; HDL high-density lipoprotein; hs-CRP high-sensitivity C-reactive protein; IDL intermediate-density lipoprotein; LDL low-density lipoprotein; TG triglyceride; VLDL very low-density lipoprotein
aIncludes all types of nicotine use
bApo CIII associated with lipoproteins that contain Apo B, excluding Apo CIII associated with HDL particles